Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · IEX Real-Time Price · USD
4.360
+0.010 (0.23%)
At close: Apr 22, 2024, 4:00 PM
4.450
+0.090 (2.06%)
Pre-market: Apr 23, 2024, 8:04 AM EDT
Cardiff Oncology Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Cardiff Oncology stock have an average target of 10.5, with a low estimate of 7.00 and a high estimate of 14. The average target predicts an increase of 140.83% from the current stock price of 4.36.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 6, 2024.
Analyst Ratings
The average analyst rating for CRDF stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $14 | Strong Buy | Maintains | $12 → $14 | +221.10% | Mar 6, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $5 → $7 | Buy | Maintains | $5 → $7 | +60.55% | Mar 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13 → $12 | Strong Buy | Maintains | $13 → $12 | +175.23% | Aug 11, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $14 → $13 | Strong Buy | Maintains | $14 → $13 | +198.17% | Aug 8, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $14 | Strong Buy | Maintains | $15 → $14 | +221.10% | May 9, 2023 |
Financial Forecast
Revenue This Year
247.35K
from 488.00K
Decreased by -49.31%
Revenue Next Year
68.00K
from 247.35K
Decreased by -72.51%
EPS This Year
-0.99
from -0.93
EPS Next Year
-1.07
from -0.99
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 808,500 | 210,000 | n/a | 31.5M | 383.3M |
| Avg | 247,350 | 68,003 | n/a | 15.4M | 372.3M |
| Low | n/a | n/a | n/a | 196,000 | 357.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 65.7% | -15.1% | - | - | 2,388.3% |
| Avg | -49.3% | -72.5% | - | - | 2,317.2% |
| Low | - | - | - | - | 2,222.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.84 | -0.84 | -1.21 | -3.77 |
| Avg | -0.99 | -1.07 | -1.35 | -3.66 |
| Low | -1.04 | -1.17 | -1.50 | -3.52 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | - |
| Avg | - | - | - | - |
| Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.